Online inquiry

IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8420MR)

This product GTTS-WQ8420MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets HSP90 gene. The antibody can be applied in Candidiasis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq XP_721353.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3636951
UniProt ID P46598
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8420MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7129MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ5510MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ11660MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ15924MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ8938MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ9963MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ13074MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ11564MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MG-A271
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW